SGLT2 Inhibitor-Related Polycythemia in a Patient With Chronic Heart Failure: A Potential Severe Adverse Event

被引：3
|
作者：
Tukker, Martijn [1 ]
Bruwiere, Ewout [1 ]
Bos, Sven [2 ]
Caliskan, Kadir [1 ,3 ]
机构：
[1] Erasmus MC Univ Med Ctr Rotterdam, Dept Cardiol, Thoraxctr, Rotterdam, Netherlands
[2] Erasmus MC Univ Med Ctr Rotterdam, Dept Haematol, Rotterdam, Netherlands
[3] Erasmus MC Univ Med Ctr Rotterdam, Dept Cardiol, Room RG 431,Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands
来源：
CIRCULATION-HEART FAILURE | 2023年 / 16卷 / 07期
关键词：
adverse drug event; dapagliflozin; erythrocytosis; heart failure; polycythemia;
D O I：
10.1161/CIRCHEARTFAILURE.123.010613
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
According to the current heart failure guidelines, SGLT2 (sodium glucose cotransporter 2) inhibitors are increasingly prescribed in patients with heart failure (HF).1 However, SGLT2-inhibitors are known to increase hemoglobin (Hb) and hematocrit (Ht) levels, but literature on SGLT2-induced erythrocytosis is limited. We provide a case of a patient with chronic HF with severe polycythemia associated with dapagliflozin usage, suggesting the potential importance of hemoglobin and hematocrit monitoring. © 2023 Lippincott Williams and Wilkins. All rights reserved.
引用
收藏
页数：3
相关论文
共 50 条
  • [21] THE SGLT2 INHIBITOR EMPAGLIFLOZIN REDUCES TISSUE SODIUM CONTENT IN PATIENTS WITH CHRONIC HEART FAILURE
    Kolwelter, Julie
    Kannenkeril, Dennis
    Linz, Peter
    Jung, Susanne
    Nagel, Armin M.
    Bosch, Agnes
    Ott, Christian
    Bramlage, Peter
    Uder, Michael
    Achenbach, Stephan
    Schmieder, Roland
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 585 - 585
  • [22] The SGLT2 inhibitor Empagliflozin shown to reduce hospitalizations for heart failure
    Idris, Iskandar
    DIABETES OBESITY & METABOLISM, 2016, 18 (01): : 110 - 110
  • [23] Kidney and heart failure outcomes associated with SGLT2 inhibitor use
    Van der Aart-van der Beek, Annemarie B.
    de Boer, Rudolf A.
    Heerspink, Hiddo J. L.
    NATURE REVIEWS NEPHROLOGY, 2022, 18 (05) : 294 - 306
  • [24] A Review of the Potential Role of Sotagliflozin: A Dual SGLT2 and SGLT1 Inhibitor-in the Treatment of Heart Failure
    Tran, Bao Anh C.
    White, Raechel T.
    Bullers, Krystal
    Cornelio, Cyrille K.
    JOURNAL OF PHARMACY TECHNOLOGY, 2024, 40 (05) : 248 - 256
  • [25] Practical Considerations and Opportunities for SGLT2 Inhibitor Prescription in Heart Failure
    Faulkenberg, Kathleen D.
    Williams, J. Bradley
    Isaacs, Diana M.
    West, Lucianne M.
    CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE, 2020, 22 (10)
  • [26] Practical Considerations and Opportunities for SGLT2 Inhibitor Prescription in Heart Failure
    Kathleen D. Faulkenberg
    J. Bradley Williams
    Diana M. Isaacs
    Lucianne M. West
    Current Treatment Options in Cardiovascular Medicine, 2020, 22
  • [27] SGLT2 inhibitor dapagliflozin lowers risk of heart failure in diabetes
    Overbeck P.
    MMW - Fortschritte der Medizin, 2018, 160 (20) : 18 - 19
  • [28] Kidney and heart failure outcomes associated with SGLT2 inhibitor use
    Annemarie B. van der Aart-van der Beek
    Rudolf A. de Boer
    Hiddo J. L. Heerspink
    Nature Reviews Nephrology, 2022, 18 : 294 - 306
  • [29] EUGLYCEMIC DKA FROM AN SGLT2 INHIBITOR IN A HEART TRANSPLANT PATIENT
    McGuiness, Mariel
    Paschke, Kelly
    Foreman, Beth
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 2268 - 2268
  • [30] RENOPROTECTIVE EFFECTS OF SGLT2 INHIBITORS AND RELATED FACTORS IN CHRONIC HEART FAILURE PATIENTS WITH DIABETES
    Horio, Takeshi
    Yokouchi, Go
    Matsumoto, Naoki
    Fukuda, Kohei
    Yoshimura, Ryutaro
    Fujiwara, Ryosuke
    Matsuoka, Yujiro
    Sakamoto, Yuya
    Fujimoto, Kohei
    Kasayuki, Noriaki
    JOURNAL OF HYPERTENSION, 2023, 41 : E309 - E310
12345